Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;61(2):196-8.
doi: 10.1016/j.jcv.2014.06.014. Epub 2014 Jun 23.

Human papilloma virions in the laboratory

Eileen F Dunne  1 , Lauri E Markowitz  1 , La'shan D Taylor  2 , Elizabeth R Unger  3 , Cosette M Wheeler  4
Affiliations
Review

Human papilloma virions in the laboratory

Eileen F Dunne et al. J Clin Virol. 2014 Oct.

Abstract

Carcinogenic human papillomaviruses (HPV) can cause cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers. Non-carcinogenic HPVs can cause anogenital warts and recurrent respiratory papillomatosis. Currently, few research laboratories propagate, isolate or generate papilloma virions. However, there have been questions about potential exposure and risk in this setting. In this brief note, we discuss the use of wild type and laboratory-generated virions in research laboratories, potential routes of laboratory exposure, and considerations for HPV vaccination of laboratory personnel.

Keywords: HPV; HPV vaccines; Human papillomavirus; Laboratory safety.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The findings and conclusions of this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the National Institutes of Health.

References

    1. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med. 2005;119:445–462. - PubMed
    1. Buck CB, Thompson CD. Production of papillomavirus-based gene transfer vectors. Current Protocols in Cell Biology. 2007;26:1–26. - PubMed
    1. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105:28–37. - PMC - PubMed
    1. CDC. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP) MMWR. 2010;59(20):626–629. - PubMed
    1. CDC. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males-Advisory Committee on Immunization Practices (ACIP) MMWR. 2011;60(50):1705–1708. - PubMed

Publication types

MeSH terms

Substances